R
Richard E. Champlin
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1500
Citations - 73470
Richard E. Champlin is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 138, co-authored 1402 publications receiving 66917 citations.
Papers
More filters
Journal ArticleDOI
Optimal Threshold and Time of Absolute Lymphocyte Count Assessment for Outcome Prediction after Bone Marrow Transplantation
Ulas D. Bayraktar,Denái R. Milton,Michele Guindani,Gabriela Rondon,Julianne Chen,Gheath Alatrash,Katayoun Rezvani,Richard E. Champlin,Stefan O. Ciurea +8 more
TL;DR: In the entire patient cohort, multivariable analyses demonstrated significantly better OS, RFS, and NRM and lower incidence of graft-versus-host disease (GVHD) in patients with an ALC >300/μL on day 60 post-BMT, both including and excluding patients who developed GVHD before day 60.
Journal ArticleDOI
Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors.
Koji Sasaki,Hagop M. Kantarjian,Nicholas J. Short,Bachar Samra,Joseph D. Khoury,Rashmi Kanagal Shamanna,Marina Konopleva,Nitin Jain,Courtney D. DiNardo,Rita Khouri,Guillermo Garcia-Manero,Tapan M. Kadia,William G. Wierda,Issa F. Khouri,Partow Kebriaei,Rohtesh S. Mehta,Richard E. Champlin,Rebecca Garris,Cora M. Cheung,Naval Daver,Philip A. Thompson,Musa Yilmaz,Farhad Ravandi,Elias Jabbour +23 more
TL;DR: In this paper, a 3-month complete molecular response (CMR) is a major prognostic factor for survival in patients with PH-positive acute lymphoblastic leukemia (ALL).
Journal ArticleDOI
Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution.
Joshua Kellner,Eveline M. Delemarre,Eric Yvon,Stefan Nierkens,Jaap Jan Boelens,Ian K. McNiece,Amanda Olson,Yago Nieto,Stefan O. Ciurea,Uday R. Popat,Sairah Ahmed,Richard E. Champlin,Jennifer D Ramos,Mitsutaka Nishimoto,Hongbing Ma,Zeng Ke,Peter F. Thall,Joseph D. Khoury,Robert S. Negrin,Borje S. Andersson,Simrit Parmar +20 more
TL;DR: Stage 2 of this clinical trial examining UCB-Treg at dose level= 1×107/kg is currently underway, and at the time of last follow up, all evaluable patients were off immune-suppression.
Journal ArticleDOI
Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography
Amer Najjar,Pallavi R. Manuri,Simon Olivares,Leo G. Flores,Tiejuan Mi,Helen Huls,Elizabeth J. Shpall,Richard E. Champlin,Nashaat Turkman,Vincenzo Paolillo,Jason Roszik,Brian Rabinovich,Dean A. Lee,Dean A. Lee,Mian M. Alauddin,Juri G. Gelovani,Laurence J.N. Cooper,Laurence J.N. Cooper +17 more
TL;DR: This is the first report demonstrating the use of SB transposition to generate T cells which may be detected using PET laying the foundation for imaging the distribution and trafficking of T cells in patients treated for B cell malignancies.